Chimerix Inc. (NASDAQ:CMRX) shares fell 2.7% on Thursday . The stock traded as low as $4.63 and last traded at $4.68, with a volume of 244,885 shares. The stock had previously closed at $4.81.

Several brokerages have recently weighed in on CMRX. FBR & Co reiterated a “hold” rating on shares of Chimerix in a report on Sunday, July 17th. Zacks Investment Research upgraded shares of Chimerix from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a report on Wednesday, August 10th. JPMorgan Chase & Co. restated a “hold” rating and issued a $7.00 price target on shares of Chimerix in a report on Tuesday, August 9th. Finally, Piper Jaffray Cos. set a $12.00 price target on shares of Chimerix and gave the company a “buy” rating in a report on Thursday, August 18th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Chimerix presently has a consensus rating of “Hold” and an average price target of $15.72.

The company’s market capitalization is $213.51 million. The firm has a 50 day moving average price of $4.33 and a 200-day moving average price of $4.81.

Chimerix (NASDAQ:CMRX) last released its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.51) by $0.12. The business had revenue of $1.80 million for the quarter, compared to analysts’ expectations of $1.98 million. On average, analysts expect that Chimerix Inc. will post ($1.78) EPS for the current fiscal year.

In other news, Director Ernest Mario purchased 50,000 shares of Chimerix stock in a transaction dated Friday, June 24th. The stock was acquired at an average cost of $3.70 per share, for a total transaction of $185,000.00. Following the acquisition, the director now directly owns 381,440 shares in the company, valued at $1,411,328. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider M Michelle Berrey purchased 22,417 shares of Chimerix stock in a transaction dated Monday, August 29th. The shares were purchased at an average price of $4.47 per share, with a total value of $100,203.99. Following the completion of the acquisition, the insider now owns 281,238 shares in the company, valued at $1,257,133.86. The disclosure for this purchase can be found here.

Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.